Patents Examined by Julie Ha
  • Patent number: 10962549
    Abstract: The present invention relates to inhibitors of HIF-1 and HIF-2 and uses thereof. The present invention further relates to the inhibitors for use in treatment of diseases. An isolated polypeptide is provided, that prevents dimerization of HIF-1? with HIF-1? and HIF-2? with HIF-1? and/or inhibits the activity of HIF-1 and HIF-2, wherein the polypeptide comprises the amino acid sequence C-X1-X2-X3-Z-X4 (SEQ ID NO 1) and wherein X1, X2, X3 and X4 are any amino acid and wherein Z is leucine, valine of isoleucine or a non-natural derivative or leucine, valine or isoleucine. The isolated polypeptide prevents dimerization of HIF-1? with HIF-1? and HIF-2? with HIF-1? and inhibits the activity of HIF-1 and HIF-2 by binding to HIF-1? or HIF-1? and/or HIF-2? or HIF-1?.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: March 30, 2021
    Assignee: UNIVERSITY OF SOUTHAMPTON
    Inventor: Ali Tavassoli
  • Patent number: 10960058
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions and pharmaceutical formulations comprising the polypeptides and polynucleotides of the disclosure and methods of using and producing same are also disclosed.
    Type: Grant
    Filed: June 19, 2016
    Date of Patent: March 30, 2021
    Assignee: OPKO BIOLOGICS LTD.
    Inventors: Udi Eyal Fima, Gili Hart
  • Patent number: 10960056
    Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: March 30, 2021
    Assignee: GemVax & KAEL Co., Ltd.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 10961295
    Abstract: Provided is a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO 105): Nter-Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-X31-X32-X33-NH2-Cter or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one biologically active single chain Relaxin peptide. Uses of the peptide or the pharmaceutical composition as a medicament are also provided.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: March 30, 2021
    Assignee: SANOFI
    Inventors: Olivier Duclos, Stéphane Illiano, Sergio Mallart, Claire Minoletti-Hochepied, Elisabetta Bianchi, Raffaele Ingenito, Paola Magotti, Alessia Santoprete
  • Patent number: 10960063
    Abstract: The present invention includes the complete genome sequence for the methanogen, Methanobrevibacter ruminan-tium, including polynucleotides which encode M. ruminantium polypeptides or peptides, as well as polynucleotides from non-coding regions. Also included are the encoded M. ruminantium polypeptides and peptides, and antibodies directed to these peptides or polypeptides, in addition to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further includes methods and compositions for detecting, targeting, and inhibiting microbial cells, especially methanogen cells such as M. ruminantium cells, using one or more of the disclosed peptides, polypeptides, polynu-cleotides, antibodies, expression vectors, and host cells.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: March 30, 2021
    Assignee: PASTORAL GREENHOUSE GAS RESEARCH LTD.
    Inventors: Eric Heinz Altermann, Graeme Trevor Attwood, Gregory Cook, Debjit Dey, Scott A. Ferguson, Petrus Hendricus Janssen, William John Kelly, Zhanhao Kong, Suzanne Lambie, Sinead Christine Leahy, Dong Li, Duncan McMillan, Sharla McTavish, Diana Pacheco, Robert Starr Ronimus, Carrie Sang, Carl Yeoman
  • Patent number: 10960051
    Abstract: Methods of treating dry eye syndrome (DES) with an effective amount of thymosin beta 4 (T?4), T?4 fragments, T?4 isoforms, T?4 derivatives, peptide agents including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO:2], or variants thereof are provided. The presently disclosed subject matter provides methods of increasing tear volume, increasing tear film stability, decreasing ocular surface damage, and decreasing ocular discomfort by delivering compositions of thymosin beta 4 or fragments thereof to subjects in need.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: March 30, 2021
    Assignee: REGENTREE, LLC
    Inventors: Won Suk Yang, Sin Wook Kang, Kyoungsun Kim
  • Patent number: 10960045
    Abstract: A method of treating epidermolysis bullosa comprising administering to a subject suffering from epidermolysis bullosa an angiotensin (1-7) peptide is described. In some embodiments, methods of treating a complication of epidermolysis bullosa are described including administering to a subject suffering from one or more complications of epidermolysis bullosa an angiotensin (1-7) peptide, wherein the administration results in a reduction in the intensity, severity, duration, or frequency of at least one symptom or feature of the one or more complications of epidermolysis bullosa.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: March 30, 2021
    Assignee: Constant Therapeutics LLC
    Inventor: Richard Franklin
  • Patent number: 10960052
    Abstract: The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 30, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Simon Bjerregaard, Flemming Seier Nielsen
  • Patent number: 10954278
    Abstract: Described are methods and associated uses for the treatment of resorptive bone disease using peptides comprising all of part of the C-terminal portion of soricidin. Also described are methods and associated uses for inhibiting osteoclast activity and/or bone resorption using the peptides.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: March 23, 2021
    Assignee: University of New Brunswick
    Inventors: Alli Murugesan, Anthony Reiman
  • Patent number: 10947276
    Abstract: A method for delivering a cargo molecule into a cell is described that comprises linking a cargo molecule to a cell penetrating peptide. Chimeric constructs comprising cell penetrating moieties are also provided.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: March 16, 2021
    Assignees: SORBONNE UNIVERSITÉ, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, PEP-THERAPY
    Inventors: Angelita Rebollo, Jesus Maria Fominaya Gutierrez, Jeronimo Bravo Sicilia, Sophie Lebel Binay, Leticia Dominguez Berrocal
  • Patent number: 10946065
    Abstract: The invention relates to methods of treating a fungal infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising one or more antifungal peptides selected from the group consisting of BmKn2, dBmKn2, Kn2-7, and dKn2-7. Antifungal pharmaceutical compositions and dosage forms, including field-deployable dosage forms, comprising one or more of these antifungal peptides are also contemplated herein.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: March 16, 2021
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventors: Nancy Millenbaugh, Jeremy Wesley Gleaton, Dickson Kiprono Kirui
  • Patent number: 10946062
    Abstract: Disclosed are methods and compositions useful in preventing or treating a metabolic disorder by using a protein having an amino acid sequence as set forth in SEQ ID NO: 1.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: March 16, 2021
    Assignee: EUSOL BIOTECH CO., LTD.
    Inventors: Jin-Ding Huang, Wan-Ya Chang, Che-Ming Yeh
  • Patent number: 10941184
    Abstract: In some aspects, the present invention cell-penetrating compstatin analog and compositions comprising cell-penetrating compstatin analog. In some aspects, the invention further provides methods of using cell-penetrating compstatin analogs treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ, to inhibit production or release of biologically active C3 cleavage products.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: March 9, 2021
    Assignee: Apellis Pharmaceuticals, Inc.
    Inventors: Cedric Francois, Pascal Deschatelets, Monica Gerber
  • Patent number: 10941183
    Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: March 9, 2021
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Ashok Bhandari, Gregory Thomas Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
  • Patent number: 10925924
    Abstract: Disclosed is a dry-powder peptide medicament with a non-typical concentration of carbohydrate excipient, as well as said medicament for use in treatment or prevention of a disease or condition, as well as methods for manufacturing said medicament.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: February 23, 2021
    Assignee: APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
    Inventor: Bernhard Fischer
  • Patent number: 10927148
    Abstract: Peptides that form adhesive bonds, even in aqueous and/or saline environments, are disclosed. When aggregated, the peptides may be used in methods for producing hydrogels and/or adhesive materials. Synthetic peptide analogs are provided that are designed based on protein sequences found in barnacle adhesive, and may optionally be augmented with chemistry from other organisms that secrete proteins that adhere to substrates. The peptides may be used, for example, in biomedical and aqueous applications. Methods of using the aggregated peptides as adhesives are also provided.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: February 23, 2021
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Christopher R. So, Kathryn J. Wahl
  • Patent number: 10918703
    Abstract: The present invention provides plant-made elafin-Fc fusion proteins for treating inflammatory diseases, e.g., inflammatory lung diseases. In certain embodiments, the fusion proteins comprise one or more point mutations, which confer improved properties, such as increased resistance to oxidation, cleavage, and increased half-life. The present invention additionally provides polynucleotides encoding the fusion proteins, recombinant cells and expression vectors, and transgenic plants comprising the fusion protein coding sequences. The present invention further provides methods for the production of the fusion proteins.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: February 16, 2021
    Assignee: The Regents of the University of California
    Inventors: Karen A. McDonald, Kalimuthu Karuppanan, Carroll E. Cross, Jason P. Eiserich
  • Patent number: 10905738
    Abstract: Synthetic peptides that are modulators of smooth muscle tone and compositions thereof, including pharmaceutical compositions containing a peptide, make it possible to treat indications in those in need of modulation of the smooth muscle tone, including, for example, benign prostate hyperplasia (BPH), Raynaud's syndrome, Pulmonary Arterial hypertension (PAH), systemic arterial hypertension (SAH) and hyper-reactivity of airways associated with asthma, COPD, pulmonary fibrosis, silicosis, allergic bronchopulmonary aspergillosis, hereditary angioedema, and neonatal hypoxemic respiratory failure. Although makeable in other ways, the synthetic peptides are makeable by recombinant methods or synthetic pathways.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: February 2, 2021
    Assignee: Biozeus Desenvolvimento De Produtos Biofarmacêuticos
    Inventors: Caio Victor Machado França do Nascimento, Diego Allonso Rodrigues dos Santos da Silva, Perla Villani Borges da Silva, Maria Elena De Lima Perez Garcia, Carolina Nunes da Silva, Adriano Monteiro de Castro Pimenta, Marcella Nunes de Melo Braga, Paulo Gustavo Sampaio Lacativa, Iron Francisco de Paula Junior, Gerhard Max Gross
  • Patent number: 10898544
    Abstract: Antiviral polypeptides and methods of use are provided herein. In particular, these polypeptides can comprise the Yodha amino acid sequence, variants, derivatives, or truncated versions thereof. In certain embodiments, this disclosure relates to uses of the peptides and compositions disclosed herein to treat or prevent a viral infection.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: January 26, 2021
    Assignees: EMORY UNIVERSITY, RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY
    Inventors: Sanil George, Joshy Jacob, David Holthausen, Song Hee Lee, Jessica Shartouny
  • Patent number: 10888606
    Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 12, 2021
    Assignee: GEMVAX & KAEL CO., LTD.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim